Citadel Advisors’s Indaptus Therapeutics INDP Stock Holding History

Citadel Advisors’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-6	Closed	-$3K	–	10134
2020 Q1	$3K	Sell	6 -4	-40%	-$3.02K	﹤0.01%	9506
2019 Q4	$11K	Buy	10 +2	+25%	+$2.76K	﹤0.01%	8998
2019 Q3	$14K	Sell	8 -9	-53%	-$26.8K	﹤0.01%	9006
2019 Q2	$168K	Buy	+17	New	+$214K	﹤0.01%	8300

Other funds holding INDP

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citadel Advisors's INDP Position: Q2 2026 in Review

Citadel Advisors sold out of Indaptus Therapeutics (INDP) in Q2 2026, closing a stake of 39,018 shares — an estimated $71K sold.

Citadel Advisors first reported a position in INDP in Q3 2019 and held it in 14 quarters. The position peaked at $160K in Q4 2020. 9 funds tracked by Wall St. Rank hold INDP as of Q2 2026.

Citadel Advisors reported no remaining Indaptus Therapeutics position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 39,018 Indaptus Therapeutics shares in Q2 2026, an estimated $71K.
Citadel Advisors first reported a position in Indaptus Therapeutics in Q3 2019 and held it in 14 quarters.
Citadel Advisors's Indaptus Therapeutics position peaked at $160K in Q4 2020.
9 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.